Effects of Psychedelic Drug Use on Neurocognitive Function and Psychological and Social Quality of Life Domains: An International Online Study
Franziska Stadler, Johan Saelens, Ioline D. Henter, Nathalie M. Rieser, Maximillian Greenwald, Elizabeth D. Ballard, Katrin H. Preller, Carlos A. Zarate, Christoph Kraus
medRxiv August 28, 2025 preprint DOI: 10.1101/2025.08.27.25334164 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Observational cohort Longitudinal |
|---|---|
| Sample size | 759 |
| Population | International online adults who reported psychedelic drug use status |
| Keywords | Neurocognitive Quality philosophy Function biology Drug Social function Applied psychology Clinical psychology Cognitive psychology Psychotherapist Cognition Social science Epistemology |
| Key findings | Recent psychedelic use is associated with lower cognitive accuracy and more depressive symptoms, while lifetime use shows no cognitive decline but lower psychosocial quality of life. |
Abstract
This international online study (N=759) examined the acute, subacute, and long-term effects of psychedelic drug use on cognitive performance and mental health. Participants completed cognitive tasks assessing working memory, selective attention, and visual/spatial perception, as well as questionnaires assessing mental health outcomes and quality of life. Based on self-reported substance use, participants were classified as non-users, lifetime users, and recent users. Recent users had significantly lower accuracy across all cognitive tasks, and lifetime users had the highest task accuracy without corresponding reaction time deficits. Lifetime use was not associated with long-term cognitive decline. Recent users reported more depressive and dissociative symptoms, whereas lifetime users reported lower scores. Lifetime users scored lower on psychological and social quality of life domains, indicating possible long-term psychosocial effects. These findings highlight the need to differentiate between the acute and long-term effects of psychedelics; lab-controlled, longitudinal studies are needed to enable safe clinical application.
Citations in the library
Cites 31
- Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms Pharmacological Reviews June 26, 2018
- Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action Neuroreport December 1, 1998
- MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine June 1, 2021
- Global Street Food: la cocina de la calle Diseño interior 2009
- Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. Pharmacology & Therapeutics May 1, 2019
and 26 more in the library